EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view

Fahimeh Lavi Arab, Akram Hoseinzadeh, Fatemeh Hafezi, Fatemeh Sadat Mohammadi, Farid Zeynali, Melika Hadad Tehran, Amirreza Rostami

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112171 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Fahimeh Lavi Arab und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Immunology Research Center, Mashhad University …. Hauptthemen laut MEDLINE: Exosomes, Prostatic Neoplasms, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 201 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer represents the second most prevalent form of cancer found in males, and stands as the fifth primary contributor to cancer-induced mortality on a global scale. Research has shown that transplanted mesenchymal stem cells (MSCs) can migrate by homing to tumor sites in the body. In prostate cancer, researchers have explored the fact that MSC-based therapies (including genetically modified delivery vehicles or vectors) and MSC-derived exosomes are emerging as attractive options to improve the efficacy and safety of traditional cancer therapies. In addition, researchers have reported new insights into the application of extracellular vesicle (EV)-MSC therapy as a novel treatment option that could provide a more effective and targeted approach to prostate cancer treatment. Moreover, the new generation of exosomes, which contain biologically functional molecules as signal transducers between cells, can simultaneously deliver different therapeutic agents and induce an anti-tumor phenotype in immune cells and their recruitment to the tumor site. The results of the current research on the use of MSCs in the treatment of prostate cancer may be helpful to researchers and clinicians working in this field. Nevertheless, it is crucial to emphasize that although dual-role MSCs show promise as a therapeutic modality for managing prostate cancer, further investigation is imperative to comprehensively grasp their safety and effectiveness. Ongoing clinical trials are being conducted to assess the viability of MSCs in the management of prostate cancer. The results of these trials will help determine the viability of this approach. Based on the current literature, engineered MSCs-EV offer great potential for application in targeted tumor therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesProstatic NeoplasmsMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansMaleAnimals

Stichwörter der Autor:innen

ExosomesMesenchymal stem cellsProstate cancerTumor microenvironment

Autor:innen und Institutionen

  • Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: LaviAF@mums.ac…
  • Department of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.; Cancer Research Center, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
  • Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Urology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Department of Biology, Faculty of Sciences, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
  • Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Zitieren

APA

Lavi Arab, F., Hoseinzadeh, A., Hafezi, F., Sadat Mohammadi, F., Zeynali, F., Hadad Tehran, M., & Rostami, A. (2024). Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112171

Vancouver

Lavi Arab F, Hoseinzadeh A, Hafezi F, Sadat Mohammadi F, Zeynali F, Hadad Tehran M, et al. Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112171

BibTeX
@article{LaviArab2024,
  author = {Lavi Arab, Fahimeh and Hoseinzadeh, Akram and Hafezi, Fatemeh and Sadat Mohammadi, Fatemeh and Zeynali, Farid and Hadad Tehran, Melika and Rostami, Amirreza},
  title = {Mesenchymal stem cell-derived exosomes for management of prostate cancer: An updated view},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112171}
}
Kostenlos starten →